UTv Videos

"I think that having some clinical guidelines would be very much beneficial for us in midlevel practice," says Adity Dutta, MSN, AGACNP-BC.

"Unique to this study is that we'll be using Orgovyx," says Kelly L. Stratton, MD, FACS.

"I'd be curious to see a validated study on whether prostate sizes have increased over time. I suspect the answer will be yes," says Joseph Song, MD.

"Pediatric patients do have a somewhat heterogeneous or variable presentation of their stone disease. A lot of that is dependent upon their age," says Katherine Chan, MD, MPH.

Ben H. Chew, MD, MSc, FRCSC, and Naeem Bhojani, MD, FRCSC, on Urology Times' recent survey of reusable vs disposable cystoscopes.

"I can say that I do see a vast number of different types of patient populations," says Adity Dutta, MSN, AGACNP-BC.

Lee discusses findings from a study presented at the 2024 American Urological Association Annual Meeting.

“We found that two-thirds or female respondents did not know their dosimeter doses during pregnancy,” says Jessica L. Wenzel, MD, MPH.

"I think pelvic pain is 1 of the areas that really needs more attention," says Gamal M. Ghoniem, MD, FACS, ABU/FPMRS.

"We provide surgical treatments for kidney stones, and we also help patients manage their stones medically; for example, helping them perhaps with spontaneous passage of their stones," says Katherine Chan, MD, MPH.

“We also saw differences in the average pay per weekday of hospital call; 32% of men reporting receiving over $500 per day [of] weekend hospital call, but only 18% of women reporting the same,” says Andrew M. Harris, MD.

"We aim to provide the best quality care we can at the locations closest to our patients," says Edward M. Schaeffer, MD, PhD.

"Especially for prostate cancer, some of the sexual side effects, it's tough to talk about that when you're talking to your uncle or your brother who has it," says Joseph Song, MD.

"When they said that they value privacy over cost and convenience, I think that is the clearest sign that the stigma for men's health still exists," says Justin M. Dubin, MD.

“It's the next evolution of being able to provide precision care for our patients in the area of prostate cancer,” says Nitin K. Yerram, MD.

"We really need better options with the least side [amount of] effects for these patients," says Zhina Sadeghi, MD.

"My hope is that from the KL2 data that I'll generate, hopefully in the next 6 to 12 months, we can apply for an RO1 to push this one step further so that we can benefit other people with brain tumors, other people with strokes, and other peoples with other neurological disorders with bladder symptoms," says Olivia H. Chang, MD, MPH, FACOG.

“Maybe the most important [finding] is that urinary tumor DNA does seem to be a good tool for detecting residual disease within this patient population,” says Joshua Linscott, MD, PhD.

“What was also interesting in our study was that when choosing a source of medications, we asked them, what made you decide to go with that option? And 62% of men said that they valued privacy above everything,” says Justin M. Dubin, MD.

“We've been developing different techniques in HoLEP, but there is a steep learning curve,” says Akhil Das, MD.

Woodson W. Smelser, MD, discusses key bladder cancer data that was presented at the 2024 AUA Annual Meeting.

"In 2015, we had 3 employed urologists in our health network. Now, we have 19 employed urologists in our health network," says Edward M. Schaeffer, MD, PhD.

"I think these findings are critical in helping us craft educational resources that would be easily understood and easily disseminated by trusted health care providers," says Stephanie Gleicher, MD, MPH.

"Our data showed that the patient regret scores were very, very low in looking at the patients that went home the same day," says David I. Lee, MD, FACS.

“The negative predictive value we want to be high, and the false positive rate we want to be low. None of those beat the radiologist reads in both of those categories,” says Robert S. Wang, MD.

"I think having success with that in humans will make [radiofrequency ablation] very, very valuable for the practicing urologist that can be done in the clinic without much training or anything like that," says Gamal M. Ghoniem, MD, FACS, ABU/FPMRS.

"We have a nice organizational framework for us to really provide effective care that really feels the same throughout the different regions," says Edward M. Schaeffer, MD, PhD.

"Glean technology is a very brilliant technology that has been developed for basically portable urodynamics," says Zhina Sadeghi, MD.